What is NDC 59762-0407?

59762-0407 is the product NDC for Risedronate Sodium, Risedronate sodium hemipentahydrate 30.1 mg/1; Risedronate sodium monohydrate 4.9 mg/1 tablet, delayed release, listed with the FDA by Mylan Pharmaceuticals, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

What is the active ingredient?

Risedronate sodium hemipentahydrate, Risedronate sodium monohydrate.

Mylan Pharmaceuticals, Inc., NDC labeler code 59762. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Risedronate Sodium?

22 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Risedronate Sodium NDC 59762-0407 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)59762-0407Labeler and product segments. Claims need a package NDC.

Product NDC at billing width59762-0407Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
59762-0407-4	5976204070459762040704	4 TABLET, DELAYED RELEASE in 1 DOSE PACK (59762-0407-4)Marketed from Mar 2, 2018

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Risedronate Sodium
Generic name (nonproprietary): risedronate sodium
Active ingredients: Risedronate sodium hemipentahydrate — 30.1 mg/1Risedronate sodium monohydrate — 4.9 mg/1
Dosage form: Tablet, Delayed release
Route: Oral
Labeler: Mylan Pharmaceuticals, Inc.NDC labeler code 59762
Product type: Prescription drug
Marketing category: NDA authorized genericApplication NDA 022560
Marketing start: Mar 2, 2018
Listing expires: Dec 31, 2027
Other FDA classes: Diphosphonates (Chemical structure)Diphosphonates (Chemical structure)
Identifiers: Product ID 59762-0407_b7e3ea01-4634-467a-b087-3d52ef7af465SPL ID b7e3ea01-4634-467a-b087-3d52ef7af465SPL set ID c89430be-15f1-4b8b-ab7e-738de716ee7dRxCUI 1020064, 1020065UNII HU2YAQ274O, F67L43UT5C
Pharmacologic class: Bisphosphonate

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N459762040704 followed by a unit qualifier and the quantity

Package 59762-0407-04. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 3, 2026.

Indications (excerpt from the label)

Risedronate sodium is a bisphosphonate in a delayed-release formulation and is indicated for treatment of postmenopausal osteoporosis ( 1.1 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use ( 1.2 ) 1.1 Postmenopausal Osteoporosis Risedronate sodium delayed-release is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women, risedronate sodium has been shown to reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [ see Clinical Studies (14.1) ] . 1.2 Important Limitations of Use The…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 59762-0407

What is NDC 59762-0407?: 59762-0407 is the product NDC for Risedronate Sodium, Risedronate sodium hemipentahydrate 30.1 mg/1; Risedronate sodium monohydrate 4.9 mg/1 tablet, delayed release, listed with the FDA by Mylan Pharmaceuticals, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Risedronate Sodium.
What is the active ingredient?: Risedronate sodium hemipentahydrate, Risedronate sodium monohydrate.
Who is the labeler?: Mylan Pharmaceuticals, Inc., NDC labeler code 59762. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Risedronate Sodium?: 22 other product NDCs are listed under this name. See all Risedronate Sodium NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Risedronate Sodium NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Risedronate Sodium	Risedronate sodium 35 mg/1	Tablet, Delayed releaseOral	Sun Pharmaceutical Industires Inc.	63304-440	63304-0440-09
Risedronate Sodium	Risedronate sodium hemi-pentahydrate 35 mg/1	Tablet, Film coatedOral	Hangzhou Minsheng Binjiang Pharmaceutical CO., Ltd	60723-041	60723-0041-0460723-0041-12
Risedronate Sodium	Risedronate sodium 150 mg/1	Tablet, Film coatedOral	Aurobindo Pharma Limited	65862-870	65862-0870-0365862-0870-11
Risedronate Sodium	Risedronate sodium 5 mg/1	Tablet, Film coatedOral	Macleods Pharmaceuticals Limited	33342-107	33342-0107-0633342-0107-0733342-0107-49
Risedronate Sodium	Risedronate sodium 30 mg/1	Tablet, Film coatedOral	Macleods Pharmaceuticals Limited	33342-108	33342-0108-0633342-0108-0733342-0108-15
Risedronate Sodium	Risedronate sodium 35 mg/1	Tablet, Film coatedOral	Macleods Pharmaceuticals Limited	33342-109	33342-0109-3733342-0109-50
risedronate sodium	Risedronate sodium hemi-pentahydrate 5 mg/1	Tablet, Film coatedOral	Sun Pharmaceutical Industries, Inc.	47335-666	47335-0666-0847335-0666-1847335-0666-83+1 more
risedronate sodium	Risedronate sodium hemi-pentahydrate 30 mg/1	Tablet, Film coatedOral	Sun Pharmaceutical Industries, Inc.	47335-667	47335-0667-0847335-0667-1847335-0667-83+1 more
risedronate sodium	Risedronate sodium hemi-pentahydrate 35 mg/1	Tablet, Film coatedOral	Sun Pharmaceutical Industries, Inc.	47335-668	47335-0668-6247335-0668-68
Risedronate Sodium	Risedronate sodium 35 mg/1	Tablet, Film coatedOral	Apotex Corp.	60505-3165	60505-3165-0060505-3165-02

All 23 Risedronate Sodium NDCs

Other NDCs under NDA 022560

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 022560
Product	Strength	Form · route	Labeler	Product NDC
Atelviarisedronate sodium	Risedronate sodium hemipentahydrate 30.1 mg/1; Risedronate sodium monohydrate 4.9 mg/1	Tablet, Delayed releaseOral	Allergan, Inc.	0430-0979